Loading
RT
Ryvu Therapeutics S.A. Stock: price and insider trades · Poland
Ryvu Therapeutics S.A.: what insiders have been doing
This page follows insider dealings at Ryvu Therapeutics S.A. as filed with KNF, a company from the Health Care sector. Between 23 October 2025 and 23 October 2026, 2 insiders published 2 filings.
No open-market purchase or sale appears among the filings, only grants, plan transactions and other operations. Such operations are usually part of compensation schedules, which makes them a weaker signal than an open-market trade.
Across the 554 companies tracked on its exchange, the median is 3 filings; at 2 filings, this issuer sits below that mark.
There has been no open-market purchase by an insider of Ryvu Therapeutics S.A. for at least a year.
Other companies in the same sector with recent insider buying flagged by our signals: Dynavox Group AB and EssilorLuxottica. These figures are compiled from regulatory filings published by KNF. They describe what insiders did and are not a recommendation.
Insider Decl.
2
Thresholds
n/a
Buy Volume
n/a
n/a
Sell Volume
n/a
n/a
Analyst consensus: bullish or bearish?
Analysts rate Ryvu Therapeutics S.A. Buy (bullish), based on 5 analysts. Average price target: PLN 29.90.
Fundamental score
Ranked 21,680 of 26,284 companies
28.6
score / 100
Value8
Quality49
FCF yld-30%
Earn yld-25%
EV/EBITDA·
ROE-40%
Gross mgn76%
Net mgn·
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
PLN 17.80
Analyst consensus
5 analystsBuy
PLN 17.00Target PLN 29.90(+68%)PLN 46.00
Income statement
RevenuePLN 62.3M
Gross profitPLN 47.5M76% margin
EBITDA-PLN 81.3M-131% margin
Net income-PLN 101.2M-81.0% margin
Valuation
PER (forward)7.3x
P/Book14.5x
Beta0.41
Balance sheet & cash
Market capPLN 411.5M
Total debtPLN 71.7M
Free Cash Flow-PLN 121.6M
Debt / Equity325%
Profitability & ownership
ROE-39.5%
ROA-11.1%
% insiders35.0%
% institutions24.3%
Last declaration on 13 April 2026
Declarations2 total
●
Executives
120,480 PLN0KNF
●
Executives
93M PLN0KNF
2 of 2 declarations
About Ryvu Therapeutics S.A.
Ryvu Therapeutics S.A. is a biopharmaceutical company focused on developing innovative cancer treatments. It is listed on the XWAR market.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
